Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug

Astellas’ Zolbetuximab Faces FDA Rejection Due to Manufacturing Facility Deficiencies

Fineline Cube Jan 9, 2024

The US Food and Drug Administration (FDA) has issued a rejection for a filing submitted...

Company Drug

3SBio Inc. Receives NMPA Approval for OTC Minoxidil Foam for Male Hair Loss Treatment

Fineline Cube Jan 9, 2024

3SBio Inc., a leading biopharmaceutical company based in China (HKG: 1530), has announced that it...

Company Deals

MSD to Acquire Harpoon Therapeutics for USD 680 Million, Expanding Its Oncology Pipeline

Fineline Cube Jan 9, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced its...

Company

Eli Lilly Appoints First Female Leader for China Unit with Huzur Devletsah at the Helm

Fineline Cube Jan 9, 2024

Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the U.S., has announced...

Company Drug

Jiangxi Jemincare Group Receives Clinical Trial Approvals for Two Innovative Biologics in the US and China

Fineline Cube Jan 9, 2024

Jiangxi Jemincare Group, a biopharmaceutical company based in China, has announced that it has received...

Company Medical Device

ShuWen Biotech’s MammaTyper Diagnostic Kit Receives NMPA Approval for Breast Cancer Molecular Classification

Fineline Cube Jan 9, 2024

ShuWen Biotech Co., Ltd, a biopharmaceutical company based in Zhejiang, has announced that its MammaTyper...

Company Drug

Allist Pharmaceuticals’ Furmonertinib and AstraZeneca’s Enhertu Earn Breakthrough Designations in China for NSCLC Treatments

Fineline Cube Jan 9, 2024

The Center for Drug Evaluation (CDE) in China has indicated on its website that Allist...

Company Drug

Thederma’s TAP-1503 Cream Receives Priority Review Status for Pediatric Atopic Dermatitis Treatment in China

Fineline Cube Jan 9, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Thederma’s TAP-1503 cream is...

Company Drug

Innovent Biologics’ Mazdutide Achieves Positive Results in Phase III Clinical Trial for Overweight or Obesity

Fineline Cube Jan 9, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Deals

Bain Capital-Backed Tenacia Strikes Deal with Praxis Precision Medicines for Essential Tremor Treatment

Fineline Cube Jan 9, 2024

Tenacia, a central nervous system (CNS) specialist incubated by Bain Capital, has entered into an...

Company Drug

Abbisko Therapeutics’ Pimicotinib Earns Orphan Drug Designation from EMA for TGCT Treatment

Fineline Cube Jan 9, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...

Company Drug

Gilead’s Descovy Receives Additional Indication Approval from China’s NMPA for HIV-1 PrEP

Fineline Cube Jan 9, 2024

Gilead Sciences, Inc. (NASDAQ: GILD), a major player in the pharmaceutical industry in the U.S.,...

Company Deals

Bebig Medical Group Secures Over USD 14 Million in Series B Financing to Boost Radiotherapy Technology

Fineline Cube Jan 9, 2024

Bebig Medical Group, a Germany-based provider of high-quality radiation therapy products with a presence in...

Company Deals

Chengdu Kanghua Strikes Licensing Deal with HilleVax for Recombinant Norovirus Vaccine

Fineline Cube Jan 9, 2024

Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...

Company Drug

CSBIO’s Multi-Kinase Inhibitor CSCJC3456 Gets Green Light for Clinical Trials in Advanced Solid Tumors

Fineline Cube Jan 9, 2024

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced...

Company Deals

Triastek Partners with Kangerjia to Develop 3D-Printed Modified Drugs for Sleep Disorders

Fineline Cube Jan 9, 2024

Triastek Inc., a China-based pharmaceutical-focused 3D printing company, has entered into a partnership with fellow...

Company Drug

Aidea Pharmaceutical Receives NMPA Approval to Clinically Test HIV-1 Treatment ACC017

Fineline Cube Jan 9, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, has announced...

Company

WuXi Biologics Expands Manufacturing Capacity to 36,000 Liters at Worcester Facility

Fineline Cube Jan 9, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Green Light for Phase Ib/II Study of SHR-A1921 Combo in Advanced Solid Tumors

Fineline Cube Jan 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Deals

Biocytogen Strikes Exclusive Licensing Deal with US-Based Radiance Biopharma for Innovative BsADC

Fineline Cube Jan 9, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a leading biopharmaceutical company based in China ,...

Posts pagination

1 … 471 472 473 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.